Lund, December 15, 2021 – Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that preclinical data for its drug candidate tasquinimod, a small molecule immunomodulator, is now available on the company’s website. The data was presented in two poster presentations at the 63rd ASH Annual Meeting and Exhibition in Atlanta, Georgia.
The results presented are part of Active Biotech’s program to address unmet medical needs to treat hematologic malignancies, including multiple myeloma. Currently, a phase Ib / IIa trial with tasquinimod in patients with multiple myeloma is underway.
“These presentations are an integral part of our clinical program around tasquinimod. The first poster is the result of our collaboration with an academic group from the Vrije Universiteit, Brussel, to deepen the study of tasquinimod in the preclinical framework of multiple myeloma. The established results validate the effect of tasquinimod in animal models of the disease and provide a better understanding of the mechanisms involved. The results presented in the second poster highlight the potential effect of tasquinimod in myelodysplastic syndrome (MDS), which could expand the potential use of tasquinimod in the hematology field. The results come from a collaboration with a university group at the University Hospital of Dresden, ”said Helén Tuvesson, CEO of Active Biotech.
The two poster presentations are:
P 1595. Tasquinimod targets immunosuppressive myeloid cells, increases osteogenesis and has direct anti-myeloma effects by inhibiting c-Myc expression in vitro and in vivo Poster Session 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster I. December 11, 2021, 5:30 pm to 7:30 pm EST. R. Fay et al., University of Vrije, Brussels, Belgium.
P 2596. Targeting of inflammatory niche in MDS by Tasquinimod restores hematopoietic support and suppresses immune checkpoint expression in vitro Poster Session 636. Myelodysplastic Syndromes – Fundamental and Translational: Poster II., December 12, 2021, 6:00 PM – 8:00 PM EST. M. Wobus et al., University Hospital Dresden, Germany.
Poster presentations are now available on the Active Biotech website. The summaries are also available on the ASH website.
For more information, please contact:
Hélène Tuvesson, CEO, +46 46 19 21 56, email@example.com
Hans Kolam, CFO, +46 46 19 20 44, firstname.lastname@example.org
This information has been submitted for publication, through the contact person indicated above, at 4:00 p.m. CET on December 15, 2021.
Tasquinimod is an investigational oral immunomodulatory and antiangiogenic treatment, which affects the ability of the tumor to grow and metastasize. Tasquinimod is being developed as a new immunomodulatory treatment for multiple myeloma. Tasquinimod has previously been studied as an anticancer agent in patients with solid cancers, including a phase 3 randomized trial in patients with metastatic prostate cancer. Tolerance of tasquinimod is well characterized on the basis of these previous experiences. Tasquinimod has demonstrated clear therapeutic potential in preclinical models of multiple myeloma, when used as monotherapy and in combination with standard treatment for multiple myeloma.
About Active Biotech AB (publ) (NASDAQ Stockholm: ACTI) is a biotechnology company deploying its vast knowledge base and portfolio of compounds to develop first-class immunomodulatory therapies for specialist indications in oncology and immunology with high unmet medical need and significant commercial potential. Following a refocusing of the portfolio, Active Biotech’s economic model aims to advance projects until the clinical development phase and then to further develop programs internally or to continue in partnership. Active Biotech currently has three projects in its portfolio: Naptumomab, a targeted anti-cancer immunotherapy, in partnership with NeoTX Therapeutics, is in a phase Ib / II clinical program in patients with advanced solid tumors. The small molecule immunomodulators tasquinimod and laquinimod, both with a mode of action that includes modulation of myeloid immune cell function, target hematologic malignancies and inflammatory eye disorders, respectively. Tasquinimod, is in clinical phase Ib / IIa for the treatment of multiple myeloma. Laquinimod is moving into a phase I clinical study with a topical ophthalmic formulation, to be followed by a phase II for the treatment of non-infectious uveitis. Please visit www.activebiotech.com for more information.
Active Biotech AB
(Company Reg.No. 556223-9227)
Scheelevägen 22, SE-223 63 Lund, Sweden
Phone: +46 (0) 46 19 20 00
211215_Presentation of the Tasquinimod ASH poster